Fredun Pharmaceuticals lifts profit 60% and declares 2:1 bonus

Fredun Pharmaceuticals ended FY26 with a 40% rise in revenue to ₹633 crore and a 60% jump in net profit to ₹33.2 crore. The company attributes these gains to cost management and operating efficiency. To mark the performance, the board declared a 2:1 bonus issue and a final dividend of 70 paise per share. The company is also preparing for future expansion by increasing its authorised share capital from ₹10 crore to ₹50 crore. These moves follow a year of capacity additions and warrant conversions. With a recent credit rating upgrade and ongoing investments in its Palghar facility, the company is signaling a shift toward a larger scale of operations. The bonus issue and capital hike are the clearest indicators that management expects this growth trajectory to continue.